Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
We have investigated the effect of atorvastatin on the endothelial function of patients with diabetes and subjects at risk for type 2 diabetes in a 12-wk , prospect i ve , r and omized , placebo-controlled , double-blind clinical trial . The flow- mediated dilation ( FMD ; endothelium dependent ) and nitroglycerin-induced dilation ( endothelium independent ) in the brachial artery and the vascular reactivity at the forearm skin were measured . FMD improved in the atorvastatin-treated , at-risk subjects [ median ( 25 - 75 percentile ) , 7.2 % ( 2.9 - 9.6 % ) at exit visit vs. 6.6 % ( 2.9 - 9.5 % ) at baseline ; P < 0.05 ] . A similar improvement of FMD was found in atorvastatin-treated  diabetic patients [ median ( 25 - 75 percentile ) , 5.6 ( 3.9 - 7.9 ) at exit visit vs. 4.2 ( 3.2 - 7.2 ) at baseline ; P = 0.07 ] . No changes were observed in nitroglycerin-induced dilation and the microcirculation reactivity measurements in either group . In the at-risk group , there was a decrease in the C-reactive protein [ median ( 25 - 75 percentile ) , 0.12 mg/dl ( 0.07 - 0.27 mg/dl ) at exit visit vs. 0.24 mg/dl ( 0.07 - 0.35 mg/dl ) at baseline ; P < 0.05 ] and TNF alpha [ median ( 25 - 75 percentile ) , 2.6 pg/ml ( 1.8 - 4.1 pg/ml ) at exit visit vs. 4.4 pg/ml ( 3.6 - 6.0 pg/ml ) at baseline ; P < 0.05 ] in the atorvastatin-treated patients , whereas in the diabetes group , a decrease in endothelin-1 ( mean + /- SD , 0.97 + /- 0.29 pg/ml at exit visit vs. 1.19 + /- 0.42 pg/ml at baseline ; P < 0.05 ) and plasminogen activator inhibitor-1 [ median ( 25 - 75 percentile ) , 18 ng/ml ( 9 - 24 ng/ml ) at exit visit vs. 27 ng/ml ( 7 - 41 ng/ml ) at baseline ; P < 0.05 ] were observed . We conclude that atorvastatin improves endothelial function and decreases levels of markers of endothelial activation and inflammation
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .